Page last updated: 2024-11-08
ammodendrine
Description
ammodendrine: structure given in first source; RN given refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ammodendrine : A piperidine alkaloid that is piperidine substituted by a 1-acetyl-1,4,5,6-tetrahydropyridin-3-yl group at position 2 (the 2R-stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (24)
Synonym |
pyridine, 1-acetyl-1,2,3,4-tetrahydro-5-(2-piperidinyl)-, (r)- |
pyridine, 1-acetyl-1,2,3,4-tetrahydro-5-(2r)-2-piperidinyl- |
isoammodendrin |
isoammodendrine |
CHEBI:2670 , |
1-acetyl-5-[(2r)-piperidin-2-yl]-1,2,3,4-tetrahydropyridine |
1-{1,2,3,4-tetrahydro-5-[(2r)-piperidin-2-yl]pyridin-1-yl}ethanone |
ammodendrine |
494-15-5 |
spherocarpine |
1-[5-[(2r)-piperidin-2-yl]-3,4-dihydro-2h-pyridin-1-yl]ethanone |
CHEMBL464777 |
d-ammodendrine |
unii-u0x8i482c7 |
u0x8i482c7 , |
ethanone, 1-(3,4-dihydro-5-(2r)-2-piperidinyl-1(2h)-pyridinyl)- |
(+)-ammodendrine |
AKOS030229934 |
Q27105761 |
DTXSID70964226 |
1-[5-(piperidin-2-yl)-3,4-dihydropyridin-1(2h)-yl]ethan-1-one |
AT20210 |
(r)-1-(5-(piperidin-2-yl)-3,4-dihydropyridin-1(2h)-yl)ethan-1-one |
1-{5-[(2r)-piperidin-2-yl]-1,2,3,4-tetrahydropyridin-1-yl}ethan-1-one |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
" The LD50 of (+)-D-ammodendrine in mice was determined to be 94." | ( Ammodendrine and N-methylammodendrine enantiomers: isolation, optical rotation, and toxicity. Chang, CW; Gardner, DR; Garrossian, M; Lee, ST; Molyneux, RJ; Panter, KE; Pfister, JA, 2005) | 2.1 |
Roles (2)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
teratogenic agent | A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
piperidine alkaloid | |
N-acylpiperidine | |
acetamides | Compounds with the general formula RNHC(=O)CH3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.88
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 21.88 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 18.60 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |